Nigeria's government has proposed a major reform to its food and medical products regulatory framework, aiming to enhance clinical trial oversight and improve public health safety. The reform, outlined in a recent report by the BusinessDay newspaper, seeks to align national regulations with international standards, particularly those of the World Health Organization.
The proposed changes include stricter guidelines for the approval of new drugs and medical devices, increased transparency in clinical trial data, and enhanced monitoring of pharmaceutical companies. The reforms also emphasize the need for greater collaboration between regulatory bodies and international health organizations.
The initiative follows years of criticism over the lack of oversight in clinical trials, which has raised concerns about the safety and efficacy of some medical products available in the country. The Nigerian National Agency for Food and Drug Administration (NAFDAC) has been under pressure to improve its regulatory processes, especially after several high-profile cases of substandard medical products entering the market.
The reform is part of a broader effort to strengthen Nigeria's healthcare infrastructure and ensure that patients have access to safe and effective treatments. It also reflects the government's commitment to aligning with global health standards and improving public trust in the country's regulatory system. The proposed changes are expected to be debated in the National Assembly in the coming months.
